Free tool
FAERS Monitor: Breo Ellipta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204275 or its brand name (Breo Ellipta, Fluticasone Furoate, Vilanterol Trifenatate). Reports on generic versions are filed under their own applications.
Reports
36,211
Serious
15,062
42% of reports
Hospitalization
7,490
Death reported
1,485
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea6,235
- drug ineffective4,089
- asthma4,061
- cough3,458
- wheezing2,688
- wrong technique in device usage process2,341
- pneumonia2,247
- product complaint1,882
- product dose omission issue1,827
- fatigue1,769
- off label use1,587
- therapeutic product effect incomplete1,553
- malaise1,479
- loss of personal independence in daily activities1,395
- headache1,364
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 6 |
| 2013 | 14 |
| 2014 | 738 |
| 2015 | 1,546 |
| 2016 | 2,738 |
| 2017 | 3,448 |
| 2018 | 4,039 |
| 2019 | 4,379 |
| 2020 | 4,480 |
| 2021 | 3,696 |
| 2022 | 2,734 |
| 2023 | 2,424 |
| 2024 | 2,390 |
| 2025 | 2,136 |
| 2026 | 1,439 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,017,948 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product complaintSignal | 1,882 | 46.5 | 44.4 | 77,657 |
| wrong technique in device usage processSignal | 2,341 | 30.6 | 29.4 | 63,771 |
| wheezingSignal | 2,688 | 27.5 | 26.5 | 65,769 |
| asthmaSignal | 4,061 | 21.6 | 21.0 | 77,361 |
| loss of personal independence in daily activitiesSignal | 1,395 | 17.3 | 16.5 | 20,892 |
| therapeutic product effect incompleteSignal | 1,553 | 12.9 | 12.3 | 16,783 |
| coughSignal | 3,458 | 7.2 | 7.0 | 18,608 |
| dyspnoeaSignal | 6,235 | 6.5 | 6.3 | 29,223 |
| pneumoniaSignal | 2,247 | 4.1 | 3.9 | 5,207 |
| product dose omission issueSignal | 1,827 | 3.6 | 3.5 | 3,498 |
| malaise | 1,479 | 2.0 | 1.9 | 709 |
| drug ineffective | 4,089 | 1.8 | 1.8 | 1,559 |
| fatigue | 1,769 | 1.3 | 1.3 | 142 |
| headache | 1,364 | 1.3 | 1.2 | 77 |
| off label use | 1,587 | 1.1 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.